Eric Benevich, Chief Commercial Officer at NEUROCRINE BIOSCIENCES INC (NBIX), sold 150,000 shares at $134.69 ($20.2M) on 2024-02-28, disclosed to the SEC on 2024-02-29.
Scheduled sale ($20.2M) by Chief Commercial Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $134.69 | 21,857 | $2.9M | 14.6% |
| 2 | $134.69 | 21,857 | $2.9M | 14.6% |
| 3 | $134.69 | 53,143 | $7.2M | 35.4% |
| 4 | $134.69 | 53,143 | $7.2M | 35.4% |
| Total | $134.69 avg | 150,000 | $20.2M | 100% |
| Filing → |
| NBIX | SELL | 2025-02-14 | $503K | — | Filing → |
| NBIX | SELL | 2025-02-12 | $232K | — | Filing → |
| NBIX | SELL | 2025-02-04 | $369K | — | Filing → |